G-protein-coupled receptor 40 agonist GW9508 potentiates glucose-stimulated insulin secretion through activation of protein kinase Cα and ε in INS-1 cells.
Animals
Calcium
/ metabolism
Cell Line, Tumor
Cell Membrane
/ drug effects
Cytosol
/ drug effects
Dose-Response Relationship, Drug
Enzyme Activation
/ drug effects
Glucose
/ pharmacology
Insulin Secretion
/ drug effects
Methylamines
/ pharmacology
Myristoylated Alanine-Rich C Kinase Substrate
/ metabolism
Propionates
/ pharmacology
Protein Kinase C-alpha
/ metabolism
Protein Kinase C-epsilon
/ metabolism
Protein Transport
/ drug effects
Rats
Receptors, G-Protein-Coupled
/ agonists
Signal Transduction
/ drug effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
05
2018
accepted:
23
08
2019
entrez:
10
9
2019
pubmed:
10
9
2019
medline:
7
3
2020
Statut:
epublish
Résumé
The mechanism by which G-protein-coupled receptor 40 (GPR40) signaling amplifies glucose-stimulated insulin secretion through activation of protein kinase C (PKC) is unknown. We examined whether a GPR40 agonist, GW9508, could stimulate conventional and novel isoforms of PKC at two glucose concentrations (3 mM and 20 mM) in INS-1D cells. Using epifluorescence microscopy, we monitored relative changes in the cytosolic fluorescence intensity of Fura2 as a marker of change in intracellular Ca2+ ([Ca2+]i) and relative increases in green fluorescent protein (GFP)-tagged myristoylated alanine-rich C kinase substrate (MARCKS-GFP) as a marker of PKC activation in response to GW9508 at 3 mM and 20 mM glucose. To assess the activation of the two PKC isoforms, relative increases in membrane fluorescence intensity of PKCα-GFP and PKCε-GFP were measured by total internal reflection fluorescence microscopy. Specific inhibitors of each PKC isotype were constructed and synthesized as peptide fusions with the third α-helix of the homeodomain of Antennapedia. At 3 mM glucose, GW9508 induced sustained MARCKS-GFP translocation to the cytosol, irrespective of changes in [Ca2+]i. At 20 mM glucose, GW9508 induced sustained MARCKS-GFP translocation but also transient translocation that followed sharp increases in [Ca2+]i. Although PKCα translocation was rarely observed, PKCε translocation to the plasma membrane was sustained by GW9508 at 3 mM glucose. At 20 mM glucose, GW9508 induced transient translocation of PKCα and sustained translocation as well as transient translocation of PKCε. While the inhibitors (75 μM) of each PKC isotype reduced GW9508-potentiated, glucose-stimulated insulin secretion in INS-1D cells, the PKCε inhibitor had a more potent effect. GW9508 activated PKCε but not PKCα at a substimulatory concentration of glucose. Both PKC isotypes were activated at a stimulatory concentration of glucose and contributed to glucose-stimulated insulin secretion in insulin-producing cells.
Identifiants
pubmed: 31498851
doi: 10.1371/journal.pone.0222179
pii: PONE-D-18-08918
pmc: PMC6733457
doi:
Substances chimiques
G-protein-coupled receptor 40, rat
0
GW9508
0
Methylamines
0
Propionates
0
Receptors, G-Protein-Coupled
0
Myristoylated Alanine-Rich C Kinase Substrate
125267-21-2
Protein Kinase C-alpha
EC 2.7.11.13
Protein Kinase C-epsilon
EC 2.7.11.13
Glucose
IY9XDZ35W2
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0222179Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Mol Cell Endocrinol. 1999 Sep 10;155(1-2):61-8
pubmed: 10580839
J Pept Res. 2000 Feb;55(2):163-72
pubmed: 10784032
J Biol Chem. 2000 Aug 25;275(34):26449-57
pubmed: 10840037
Annu Rev Pharmacol Toxicol. 2001;41:145-74
pubmed: 11264454
Endocrinology. 2002 Nov;143(11):4203-9
pubmed: 12399413
J Biol Chem. 2003 Mar 28;278(13):11303-11
pubmed: 12496284
J Biol Chem. 2003 Mar 14;278(11):9896-904
pubmed: 12514176
Nature. 2003 Mar 13;422(6928):173-6
pubmed: 12629551
Pharmacol Toxicol. 2003 Jan;92(1):3-13
pubmed: 12710591
J Biol Chem. 2003 Nov 7;278(45):44753-7
pubmed: 12941947
Endocrinology. 1992 Jan;130(1):167-78
pubmed: 1370150
Diabetes. 2004 Jan;53(1):5-13
pubmed: 14693691
Drugs. 2004;64(12):1339-58
pubmed: 15200348
J Physiol. 2004 Nov 15;561(Pt 1):133-47
pubmed: 15388777
J Membr Biol. 2004 Jul 15;200(2):57-66
pubmed: 15520904
Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E670-7
pubmed: 15914509
Cell Tissue Res. 2005 Nov;322(2):207-15
pubmed: 16044321
Biochem Biophys Res Commun. 2005 Sep 16;335(1):97-104
pubmed: 16081037
Biochem Biophys Res Commun. 2005 Dec 30;338(4):1788-90
pubmed: 16289108
Curr Pharm Des. 2006;12(4):485-501
pubmed: 16472141
Diabetologia. 2006 May;49(5):962-8
pubmed: 16525841
Br J Pharmacol. 2006 Jul;148(5):619-28
pubmed: 16702987
Cell Signal. 2006 Sep;18(9):1360-5
pubmed: 16716567
Diabetologia. 2006 Jul;49(7):1578-86
pubmed: 16752176
J Clin Invest. 2006 Jul;116(7):1802-12
pubmed: 16823478
J Biol Chem. 2006 Sep 29;281(39):28499-507
pubmed: 16870611
Diabetes. 2006 Dec;55 Suppl 2:S16-23
pubmed: 17130640
Diabetes. 2007 Apr;56(4):1087-94
pubmed: 17395749
Expert Opin Ther Targets. 2007 May;11(5):661-71
pubmed: 17465724
Diabetes. 2008 Aug;57(8):2211-9
pubmed: 18477808
Biochim Biophys Acta. 2008 Oct;1783(10):1929-34
pubmed: 18486624
Pharmacol Rev. 2008 Dec;60(4):405-17
pubmed: 19047536
Nat Rev Drug Discov. 2009 May;8(5):369-85
pubmed: 19365392
Adv Exp Med Biol. 2010;654:91-114
pubmed: 20217496
FASEB J. 2013 Apr;27(4):1610-20
pubmed: 23299857
Diabetes. 2013 Oct;62(10):3316-23
pubmed: 23818527
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
Nature. 1989 Sep 21;341(6239):197-205
pubmed: 2550825
J Clin Invest. 2015 Dec;125(12):4714-28
pubmed: 26571400
Biochem J. 1989 Nov 15;264(1):27-33
pubmed: 2690823
Sci Rep. 2016 May 16;6:25912
pubmed: 27180622
J Biol Chem. 2016 Jul 15;291(29):14986-95
pubmed: 27226533
Pharmacol Res Perspect. 2016 Apr 27;4(3):e00237
pubmed: 27433346
FASEB J. 2017 Mar;31(3):1028-1045
pubmed: 27927723
Endocrinology. 1987 Sep;121(3):1025-33
pubmed: 3304975
Cancer Res. 1980 Oct;40(10):3827-31
pubmed: 6254641
Cell. 1995 Jan 27;80(2):259-68
pubmed: 7834745
J Biol Chem. 1993 Jan 25;268(3):1501-4
pubmed: 8420923
J Biol Chem. 1997 Jan 17;272(3):1417-20
pubmed: 8999804
Am J Physiol. 1997 Jan;272(1 Pt 1):C263-9
pubmed: 9038832
Biochem J. 1998 Jun 1;332 ( Pt 2):281-92
pubmed: 9601053
Trends Cell Biol. 1998 Feb;8(2):84-7
pubmed: 9695814
J Cell Biol. 1998 Oct 19;143(2):511-21
pubmed: 9786959